Key Highlights

  • Adjusted EBITDA grew 32 percent year over year to $20 million, with Margin expanding to 41 percent as profit growth outpaced Revenue growth.
  • Revenue of $49.2 million beat the $45.4 million estimate by 8.41 percent, while adjusted EPS of $0.10 missed the $0.12 estimate by 16.67 percent.
  • Clinic count reached 287 locations, up 34 year over year, with trailing 12-month customer visits up 10 percent to 6.92 million and same-clinic revenue up 6 percent.
  • Management expects new AI-enabled service fee increases to add approximately JPY 15 million per year in incremental revenue, with most of the benefit falling directly to profit given the fixed-cost nature of the underlying services.

Profit Growth Outpaces Revenue as Structural Reforms Complete

SBC Medical Group Holdings Incorporated (NASDAQ:SBC), a Japan-based operator and management services provider to a network of aesthetic and healthcare clinics, reported second-quarter revenue of $49 million, up 13 percent year over year, while adjusted EBITDA grew 32 percent to $20 million, lifting margin to 41 percent. Management characterized the quarter as the culmination of structural reforms undertaken throughout 2025, with the growth driven primarily by expansion of the company's points-based management services Business following a June 2025 change in operating policy, alongside revisions to certain service fees.

The results were achieved despite a weaker Japanese yen creating a translation headwind, since the substantial majority of the company's business is conducted in yen. Same-clinic revenue rose 6 percent, average spend per visit increased 9 percent, and trailing 12-month customer visits grew 10 percent to 6.92 million, with management pointing to simultaneous growth in both customer Volume and pricing as evidence of renewed underlying strength across the clinic network.

Multi-Brand Aesthetic Strategy Expands Alongside New Non-Aesthetic Push

The company continued executing its multi-brand strategy in aesthetic dermatology, renaming its Shonan Aesthetic Dermatology Brand to SBC Skin Clinic to lower the barrier to entry for customers seeking basic dermatological treatments, while adding new NEO Skin Clinic and JUN Clinic locations targeting higher-value, beauty-conscious customers. The company also launched two new formats aimed at men's aesthetics, a large-scale hair removal format called THE LASER and a specialized beard removal clinic called SBC Men's Flash Clinic, building on Gorilla Clinic's first-half transaction value growth of 19 percent.

Non-aesthetic healthcare, which still represents only about 16 percent of the company's transaction value mix against 84 percent for aesthetic services, was identified as the company's second major growth engine, with a dedicated team established in June 2026 under a newly hired executive to sharpen both customer Acquisition and medical management across existing clinics while pursuing acquisitions to expand location count. Management said the relatively small current share of non-aesthetic revenue represents significant untapped upside as the strategy scales.

AI Investment and U.S. Partnership Support International Expansion

Management detailed a growing suite of AI tools deployed across clinic operations, including an AI chatbot for round-the-clock customer inquiries, an AI interpreter supporting English and Chinese inbound patients, and a planned AI call center expected to launch later in 2026, alongside AI tools supporting new clinic site selection and knowledge sharing across the company's 26-year operating history. Enhanced call center functionality and stronger support for its Gorilla and Rize clinic brands are together expected to add approximately JPY 15 million in annual service fee revenue, with management noting most of this flows directly to profit given the largely fixed-cost nature of the underlying support services.

In the U.S., the company continues advancing its collaboration with OrangeTwist, a medical spa operator with 24 locations across six states in which SBC holds a minority stake, crediting a recent change in OrangeTwist's Leadership with accelerating the pace of operational improvements including procurement cost reductions and revised marketing strategy. Management said it is considering increasing its ownership stake in OrangeTwist and is evaluating both organic expansion and additional M&A as paths to scale the U.S. business, while continuing to develop an asset-light Franchise model in Southeast Asia starting with its first Thai clinic.

Long-Term Target of 1,000 Clinics by 2035 Anchors Capital Allocation Strategy

Management reiterated a long-term target of 1,000 clinics by 2035, up from close to 300 today, with the expectation that non-aesthetic categories including orthopedics, ophthalmology, and fertility treatment will represent a substantially larger share of the business a decade from now than the current aesthetic-dominated mix. The company's net cash position stood at approximately 45 percent of market capitalization, which management said provides ample capacity to fund both organic growth and disciplined M&A, alongside continued Investor relations efforts in New York and Hong Kong aimed at broadening its Shareholder base, which has grown roughly 4.7 times year over year as of July 2026. Whether the company can sustain profit growth outpacing revenue growth will likely depend on how quickly its AI-driven service fee increases scale across the network, and how successfully the newly formed non-aesthetic healthcare team can convert the category's currently modest 16 percent revenue share into a more meaningful growth contributor.